Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (67)

III-01Elin Boger

Drug targeting in pulmonary sub-epithelial compartments predicted through systems pharmacology modelling

Thursday 09:50-11:20

III-02Esther Encinas

Application of modelling and simulation (M&S) methods within the context of a paediatric-use marketing authorisation (PUMA) application

Thursday 09:50-11:20

III-03Elvira Erhardt

Comparison of pharmacokinetic parameters estimated by the experimental R package ‘nlmixr’ and MONOLIX

Thursday 09:50-11:20

III-04Ruben Faelens

Clinical trial optimization of efficacy studies in slowly progressive diseases

Thursday 09:50-11:20

III-05Kevin Feng

Study and application of nonparametric and parametric population modeling for automatic subpopulation classification to CYP2D6 phenotype compounds and pediatric age groups

Thursday 09:50-11:20

III-06Cecilia Fosser

Model based predictions of the PTG-100 pharmacodynamic responses in ulcerative colitis patients

Thursday 09:50-11:20

III-07Jose Francis

Influence of nevirapine and ritonavir/lopinavir based antiretroviral therapy on Lumefantrine exposure in HIV-1 infected patients.

Thursday 09:50-11:20

III-08Aline Fuchs

Minimization of a utility function for optimizing the dosing frequency of amoxicillin administration in neonates according to a fixed PK/PD index

Thursday 09:50-11:20

III-09Saskia Fuhrmann

Model-based comparison of mAb clearance in pediatric populations*

Thursday 09:50-11:20

III-10María García-Cremades

Mechanistic multi-scale systems pharmacokinetics model applied for the anticancer drug gemcitabine in pancreatic cancer

Thursday 09:50-11:20

III-11Iain Gardner

A Whole body Physiologically based Pharmacokinetic Model for Antibody drug conjugates – model development and validation in rat

Thursday 09:50-11:20

III-13Silke Gastine

Population Pharmacokinetics of Micafungin in critically ill patients – evaluation of a fixed dose regimen

Thursday 09:50-11:20

III-14Francois Gaudreault

Circadian quantitative system pharmacology model to inform clinical study design and translation to human

Thursday 09:50-11:20

III-15Parviz Ghahramani

Antimicrobial Drug Development Common Practices in PK-PD Model Selection and Common Misconceptions

Thursday 09:50-11:20

III-16Anais Glatard

Varenicline exposure is associated with abstinence from smoking in a cohort of smokers from the general population

Thursday 09:50-11:20

III-17Ignacio Gonzalez-Garcia

Comparison of FO – FOCE population parameter estimation methods in PhysPK 2.0 against NONMEM 7.3

Thursday 09:50-11:20

III-18Sungwoo Goo

Population pharmacokinetics(PK)/Pharmacodynamics(PD) modeling and simulation of vancomycin in pediatric infectious patients

Thursday 09:50-11:20

III-19Verena Gotta

Conceptual evaluation of urea rebound in pediatric hemodialysis patients by a physiology-based pharmacokinetic simulation study

Thursday 09:50-11:20

III-20Sebastiaan Goulooze

Kernel-based visual hazard comparison (kbVHC): a simulation-free diagnostic for parametric repeated time-to-event models

Thursday 09:50-11:20

III-21Silvia Grandoni

Evaluation of a minimal WB-PBPK platform supporting different routes of administration

Thursday 09:50-11:20

III-22Ana-Marija Grisic

Towards understanding the loss of response to infliximab in patients with inflammatory bowel disease: A population PK modelling approach

Thursday 09:50-11:20

III-23Benjamin Guiastrennec

Model-based prediction of plasma concentration and enterohepatic circulation of total bile acids in human

Thursday 09:50-11:20

III-24Monia Guidi

Adequacy of open-loop Target Controlled Infusion devices during anesthesia

Thursday 09:50-11:20

III-25Anubha Gupta

Power calculation methods to detect covariates effect when combining observed and simulated data.

Thursday 09:50-11:20

III-26Serge Guzy

Population Pharmacokinetic of L-DOPA and its main metabolites: Use of the Phoenix based QRPEM algorithm

Thursday 09:50-11:20

III-27Bengt Hamrén

Pharmacokinetic and exposure-response analyses supporting ticagrelor dosing recommendation in patients with prior myocardial infarction (PEGASUS-TIMI 54)

Thursday 09:50-11:20

III-28Nina Hanke

Physiologically-based pharmacokinetic (PBPK) modeling of alfentanil as a CYP3A4 victim drug

Thursday 09:50-11:20

III-29Niklas Hartung

Quantifying adaptive resistance in bacteria using well-designed dynamic time-kill curve experiments

Thursday 09:50-11:20

III-30Paul Healy

Impact of metabolic polymorphism on the exposure to tramadol and its active metabolite in children

Thursday 09:50-11:20

III-31Lee Heechan

A population parmacokinetic analysis of fimasartan, a novel angiotensin-receptor antagonist, in healthy subjects and patients with hypertension

Thursday 09:50-11:20

III-32Eleanor Howgate

Sensitivity analysis of P-glycoprotein Ki values in dynamic DDI predictions

Thursday 09:50-11:20

III-33Gailing Li

Mechanism-Based Modeling In Chronic Heptatis B

Thursday 09:50-11:20

III-34Moustafa M. A. Ibrahim

Model-based diagnostics post-processing for fast automated model building; show-cased with residual error models and CWRES.

Thursday 09:50-11:20

III-35Ibrahim Ince

Extension of a pregnancy physiologically-based pharmacokinetic model for renally cleared drugs to the postpartum period

Thursday 09:50-11:20

III-36Itziar Irurzun-Arana

Population PD modelling of circulating biomarkers in patients with melanoma treated with interferon alpha2b

Thursday 09:50-11:20

III-37Masoud Jamei

Virtual Bioequivalence Assessment of Two Tramadol Formulations using the Advanced Dissolution Absorption and Metabolism (ADAM) model via Simcyp R Package

Thursday 09:50-11:20

III-38Candice Jamois

Quantification of Anti-Drug-Antibodies (ADA) Impact on Drug Exposure Using a Population PK modeling Approach

Thursday 09:50-11:20

III-39Julie Janssen

Clinical trial simulations to optimize dose finding studies in paediatric oncology

Thursday 09:50-11:20

III-40Jihyun Jeon

Pharmacokinetic modeling of Donepezil after transdermal administration in rat

Thursday 09:50-11:20

III-41Jin Jin

Crenezumab exposure-response across Alzheimer’s Disease endpoints supports a higher dose for Phase 3

Thursday 09:50-11:20

III-42Martin Johnson

Exposure response relationship for interstitial lung disease (ILD) events following osimertinib treatment

Thursday 09:50-11:20

III-43Koen Jolling

CHF5993 a triple combination therapy for COPD patients: population pharmacokinetic modelling of beclometasone-17-monopropionate (B17MP) following pMDI inhalation.

Thursday 09:50-11:20

III-44Siv Jonsson

Placebo and drug response assessment on Unified Parkinson’s Disease Rating Scale using longitudinal Item Response Modelling

Thursday 09:50-11:20

III-45Matts Kågedal

Herceptin in HER2-positive Gastric Cancer: Evaluation of Exposure-Response with Two Dose Levels.

Thursday 09:50-11:20

III-46Vangelis Karalis

On the population pharmacokinetics and the enterohepatic recirculation of inhaled formoterol in asthma patients

Thursday 09:50-11:20

III-47Johannes Kast

Antibiotic Efficacy during Spaceflight: Impact of Simulated Microgravity on Killing of S. pneumoniae by Ciprofloxacin

Thursday 09:50-11:20

III-48Tatiana Khariton

Human Population PK Model, Dose Selection and Target Attainment Simulations for CF-301 – a Novel Antibacterial Lysin

Thursday 09:50-11:20

III-49Yu Kyong Kim

Population Pharmacokinetic Model Development for Long-Acting Intramuscular Injection of Drug X in Healthy Subjects

Thursday 09:50-11:20

III-50Yun Kim

A population pharmacokinetic analysis of voriconazole according to CYP2C19 phenotype in healthy subjects

Thursday 09:50-11:20

III-51Lena Klopp-Schulze

Exploring and explaining variability in tamoxifen and endoxifen pharmacokinetics in breast cancer patients: A pooled analysis

Thursday 09:50-11:20

III-52Frank Kloprogge

Pharmacodynamics of vancomycin in children

Thursday 09:50-11:20

III-53Ben Kluender

Pharmacokinetic and Exposure-Response Analyses for Extrapolation of Efficacy of Adalimumab in Adolescent Patients with Hidradenitis Suppurativa‎

Thursday 09:50-11:20

III-54Franziska Isabelle Kluwe

Population pharmacokinetics of unbound voriconazole following two different routes of administration during sequence therapy

Thursday 09:50-11:20

III-55Jane Knöchel

A novel measure of importance of state variables for model reduction: results for the blood coagulation network

Thursday 09:50-11:20

III-56Gilbert Koch

Characterization of heart rate and sleeping patterns in pre-term neonates

Thursday 09:50-11:20

III-57Yuri Kosinsky

Radiation and anti-PD-L1 treatment combinations: Immune cell responses and dose scheduling optimization using a joint experimental and systems modeling approach

Thursday 09:50-11:20

III-58Pavel Kovalenko

Pharmacodynamic (PD) model of neutrophil margination to describe transient effect of sarilumab on absolute neutrophil count (ANC) in patients with rheumatoid arthritis (RA) after single-dose administration

Thursday 09:50-11:20

III-59Anu Shilpa Krishnatry

Population pharmacokinetics and pharmacodynamics of GSK525762 in patients with solid tumors

Thursday 09:50-11:20

III-60Anders Kristoffersson

A Novel Mechanism-Based Pharmacokinetic-Pharmacodynamic Model Describing Ceftazidime-Avibactam (CAZ-AVI) Efficacy Against β-lactamase-Producing Klebsiella pneumoniae and Pseudomonas aeruginosa Isolates

Thursday 09:50-11:20

III-61Fabiola La Gamba

A Bayesian PK/PD model for synergy; a case study

Thursday 09:50-11:20

III-62

Population pharmacokinetics of Rimeporide: a sodium-hydrogen exchanger (NHE-1) inhibitor for patients with Duchenne Muscular Dystrophy (DMD)

Thursday 09:50-11:20

III-63Silvia Maria Lavezzi

Modelling of rituximab clearance reduction due to ibrutinib co-administration

Thursday 09:50-11:20

III-64Jacob Leander

Pharmacodynamic modeling of uric acid turnover and the effect of Verinurad (RDEA3170), a novel selective uric acid reabsorption inhibitor for the treatment of gout and asymptomatic hyperuricemia

Thursday 09:50-11:20

III-65Jong Bong Lee

In silico modelling of chylomicron association to predict lymphatic absorption of small molecules

Thursday 09:50-11:20

III-66Donghwan Lee

Population pharmacokinetic analysis of meropenem in Korean patients with acute infections

Thursday 09:50-11:20

III-67Jennifer Leohr

A Semi-Physiologic Model of Postprandial Triglyceride Response following Anti-Obesity Therapy

Thursday 09:50-11:20

III-68Sarah Lezzar

Population pharmacokinetics and pharmacodynamics analysis of hydroxyurea, in adult patients with sickle cell anemia (SCA), and evaluation of disease markers

Thursday 09:50-11:20